3M (MMM) Stock Analysis 2026: A Dividend King Rebuilding After the Storm

title: "3M (MMM) Stock Analysis 2026: A Dividend King Rebuilding After the Storm" description: "Deep dive 3M (MMM) stock analysis for 2026. Graham Number, intrinsic value, Piotroski F-Score, and honest verdict on this 66-year dividend payer post-spinoff." date: "2026-03-06" category: "Stock Analysis" author: "Poor Man's Stocks" image: "/images/blog/mmm-stock-analysis.jpg"

3M used to be the most boring stock in every retiree's portfolio. Sixty-six consecutive years of dividend increases. A diversified industrial giant making everything from Post-it Notes to surgical tape. The kind of stock your grandpa bought and forgot about.

Then everything went sideways. PFAS lawsuits. Earplug litigation. A healthcare spinoff. And yes — a dividend cut that technically ended one of the longest streaks in corporate America.

So where does that leave 3M in 2026? Is this a fallen king staging a comeback, or a value trap disguised in industrial clothing?

Let us dig into the real numbers.

3M at a Glance: Key Metrics (March 2026)

| Metric | Value | |---|---| | Stock Price | $156.21 | | Market Cap | $82.28B | | Revenue (FY 2025) | $24.95B | | Net Income (FY 2025) | $3.25B | | EPS (Diluted) | $6.00 | | P/E Ratio | 26.04 | | Forward P/E | 18.04 | | Dividend Per Share | $3.12 | | Dividend Yield | 1.94% | | Payout Ratio | 52.00% | | Book Value Per Share | $8.69 | | Free Cash Flow | $1.40B | | FCF Per Share | $2.58 | | Debt to Equity | ~7.0x | | Beta | 1.15 |

Data sourced from StockAnalysis.com as of March 2026.

Wait — Is 3M Still a Dividend King?

Let us address the elephant in the room first.

In April 2024, 3M spun off its healthcare business into a separate company called Solventum (SOLV). As part of that spinoff, 3M cut its quarterly dividend from $1.51 per share to $0.70 — a reduction of more than 50%.

Technically, that breaks the streak. You cannot cut your dividend by half and claim you "increased" it. However, 3M's management — and some dividend tracking services — argue the cut was proportional to the business that left. The remaining industrial 3M inherited a right-sized payout.

Here is the honest take: the 66-year streak is functionally over. But the new 3M has already started increasing again — from $0.70/quarter to $0.73, and now $0.78 as of February 2026. That is a 4.95% trailing growth rate. The company is building a new streak from the ground up.

If you are a strict Dividend King purist, 3M is disqualified. If you care about the intent and trajectory, 3M is clearly recommitted to dividend growth.

Revenue and Earnings: The Post-Spinoff Picture

Here is where things get interesting. With Solventum gone, 3M is a leaner, more focused industrial company:

| Year | Revenue | EPS (Diluted) | FCF | |---|---|---|---| | 2021 | $35.36B | $10.12 | $5.85B | | 2022 | $26.16B | $10.18 | $3.84B | | 2023 | $24.61B | -$12.63 | $5.07B | | 2024 | $24.58B | $7.55 | $638M | | 2025 | $24.95B | $6.00 | $1.40B |

A few things jump out:

Revenue has stabilized around $25B after the spinoff and litigation charges. Growth is minimal at 1.5% year-over-year, but the bleeding has stopped.
2023 was a nightmare year — that -$12.63 EPS was driven by massive litigation reserves for the PFAS and earplug settlements. The company took billions in charges.
FCF is recovering but still weak. The $1.40B in 2025 is a far cry from the $5B+ levels of 2021-2023. This is partly due to litigation settlement cash outflows.
EPS declined 20.5% from 2024 to 2025, which is concerning. Part of this is the continued cost of unwinding legal issues.

Graham Number Calculation

The Graham Number uses Benjamin Graham's formula to estimate a stock's fair value based on earnings and book value:

Graham Number = √(22.5 × EPS × Book Value Per Share)

For 3M:

EPS (Diluted, TTM) = $6.00
Book Value Per Share = $8.69

Graham Number = √(22.5 × 6.00 × 8.69) Graham Number = √(1,173.15) Graham Number = $34.25

3M currently trades at $156.21 — that is more than 4.5x its Graham Number. By Benjamin Graham's strict value criteria, 3M is wildly overvalued.

But context matters. 3M's book value has been decimated by years of litigation charges and the Solventum spinoff. The book value per share of $8.69 is arguably artificially depressed. When a company takes $15B+ in legal charges, it shreds book value without necessarily destroying the earning power of the business.

For a more realistic intrinsic value estimate, let us use a Discounted Cash Flow approach.

DCF-Based Intrinsic Value Estimate

Using conservative assumptions:

Current FCF: $1.40B (depressed by litigation payments)
Normalized FCF: ~$3.5B (management's target range)
Growth Rate: 3% (conservative for industrials)
Discount Rate: 9%
Terminal Multiple: 15x FCF

Normalized FCF of $3.5B × 15 = $52.5B enterprise value. Subtract ~$6.7B net debt = ~$45.8B equity value ÷ 537M shares = ~$85 per share.

Even with normalized FCF, 3M looks expensive at $156. The market is pricing in a significant earnings recovery that has not materialized yet.

Piotroski F-Score Assessment

The Piotroski F-Score rates a stock from 0-9 based on financial health. Let us score 3M:

| Criteria | Pass/Fail | Notes | |---|---|---| | Positive Net Income | ✅ Pass | $3.25B net income | | Positive Operating Cash Flow | ✅ Pass | Operating cash flow positive | | ROA Increasing | ❌ Fail | Net income declined 22% YoY | | Cash Flow > Net Income | ❌ Fail | FCF of $1.40B < $3.25B net income (accruals concern) | | Declining Long-Term Debt | ✅ Pass | LT debt down from $11.13B to $10.93B | | Current Ratio Improving | ✅ Pass | Current ratio improved with asset optimization | | No Share Dilution | ✅ Pass | Shares decreased 2% YoY (buybacks) | | Gross Margin Improving | ❌ Fail | Gross margin declined from 41.2% to 39.9% | | Asset Turnover Improving | ✅ Pass | Revenue/assets improved slightly |

Estimated Piotroski F-Score: 6/9 — Decent but not strong. The declining margins and earnings quality are yellow flags.

The Bull Case: A Leaner, Meaner 3M

| Bull Case Factors | Details | |---|---| | Post-Spinoff Focus | Without healthcare, 3M can focus on its industrial, safety, transportation, and electronics businesses | | Litigation Resolution | The PFAS and earplug settlements, while expensive, provide clarity. The worst is known. | | Margin Recovery | Management targeting return to 20%+ operating margins (currently 18.6%) | | Innovation Pipeline | 3M still holds 100,000+ patents and invests $1.2B/year in R&D | | Dividend Restart | New dividend streak with 4.95% growth shows commitment | | Buybacks | Share count declining 2% annually — returning capital to shareholders | | Analyst Consensus | Average price target of $174.78 (+11.9% upside) |

The bull thesis is essentially: "The pain is priced in, and the new 3M will emerge stronger." Management has been cutting costs aggressively and targeting normalized FCF of $3.5B+, which would support a much higher dividend over time.

If 3M can execute on margin expansion and the litigation payments wind down (expected mid-2027 for the bulk of PFAS payments), free cash flow could double or triple from current levels.

The Bear Case: Still Too Many Uncertainties

| Bear Case Factors | Details | |---|---| | PFAS Overhang | Total settlement exposure estimated at $10-12B over several years. Cash outflows ongoing. | | Revenue Stagnation | 1.5% growth is barely above inflation. Organic growth has been declining. | | Margin Compression | Gross margins dropped from 47% (2021) to under 40%. Structural, not temporary. | | Weak FCF | $1.40B is well below the $5B+ historical norm. Recovery timeline uncertain. | | Overvalued | P/E of 26 for a company with declining earnings is hard to justify | | Forward P/E Gap | Forward P/E of 18 implies analysts expect big EPS growth — risky bet | | Lost Dividend King Status | Income investors who held for the streak may not come back |

The bear case comes down to one question: "Why pay 26x earnings for a company with flat revenue, declining margins, and litigation headwinds?"

Compared to other industrials like Honeywell (HON) or Illinois Tool Works (ITW), 3M does not screen well on growth or margins. The premium feels like nostalgia pricing.

3M vs. Other Dividend Kings

How does 3M compare to our other Dividend King analyses?

| Stock | Yield | P/E | Payout Ratio | FCF Growth | |---|---|---|---|---| | MMM | 1.94% | 26.04 | 52% | +119% (off low base) | | KO | 2.71% | 25.69 | 68% | Stable | | PG | 2.40% | ~25 | ~60% | Steady | | JNJ | ~3.2% | ~15 | ~45% | Strong |

3M offers the lowest yield with arguably the highest risk among these Dividend Kings. JNJ gives you a higher yield with a lower P/E. KO gives you a better moat. PG gives you more consistent growth.

Our Honest Verdict: HOLD (If You Own) / AVOID (New Money)

Here is the uncomfortable truth: 3M is a turnaround story being priced like a growth stock.

At $156, you are paying 26x earnings for 1.5% revenue growth and declining margins
The Graham Number of $34 screams overvaluation, even accounting for depressed book value
FCF has not recovered enough to justify the current market cap
The dividend yield of 1.94% is below even a high-yield savings account
Forward P/E of 18 bakes in a 45% earnings improvement that is far from guaranteed

If you already own 3M, holding is reasonable. The company is not going bankrupt, litigation is being resolved, and the dividend is growing again. A 3-5 year time horizon could work if management executes on margin recovery.

If you are looking to put new money to work, there are better options in the Dividend King space. Coca-Cola offers a better moat. Johnson & Johnson offers better value metrics. Even AT&T — with all its problems — offers a higher yield at a lower P/E.

3M might become a great buy again at $100-110 (where the Graham Number and DCF would converge toward fair value). At $156? The risk/reward tilts bearish.

Our Rating: HOLD / SPECULATIVE

Ready to Start Building Your Dividend Portfolio?

Whether 3M makes your list or not, the key is getting started. These brokerages offer commission-free trading and fractional shares — perfect for building positions over time:

👉 Open a Moomoo account — Get free stocks + powerful screening tools to find undervalued dividend payers

👉 Open a Webull account — Commission-free trading with excellent charting for tracking your positions

Tools to Do Your Own Analysis

Do not just take our word for it. Run the numbers yourself:

🧮 Graham Number Calculator — Calculate fair value for any stock
📊 Piotroski F-Score Calculator — Score a stock's financial health (0-9)
📖 Benjamin Graham's 7 Criteria — The value investing checklist
🚩 Value Trap Warning Signs — How to spot stocks that look cheap but aren't

Disclaimer: This article is for educational purposes only. It is not financial advice. We may earn commissions from affiliate links. Always do your own research before investing. Data sourced from StockAnalysis.com as of March 2026.

Understanding 3M's Business After the Spinoff

If you are new to 3M, it helps to understand what the company actually does now that Solventum has taken the healthcare business.

The "new" 3M operates in four main segments:

Safety & Industrial (Largest Segment)

This includes personal protective equipment (N95 masks made 3M a household name during COVID), adhesives and tapes for industrial use, abrasives, and automotive aftermarket products. This segment generates roughly 40% of total revenue and is the core of 3M's identity.

Transportation & Electronics

Think automotive films, electronic materials, display films for screens, and advanced materials for electric vehicles. This is the growth segment — EV adoption and electronics miniaturization are secular tailwinds.

Consumer

Post-it Notes, Scotch Tape, Command Hooks, Filtrete air filters. These are the brands you know from the hardware store. Stable, mature, and cash-generative but not growing fast.

Corporate & Other

Includes licensing income from 3M's massive patent portfolio and corporate overhead.

The key insight: 3M is now a purer industrial play. Without healthcare dragging down or boosting results, the company's performance will be driven by industrial production, automotive trends, and construction activity. This makes 3M more cyclical than it was before — something to keep in mind if a recession hits.

The PFAS Elephant: How Big Is the Risk?

You cannot analyze 3M without confronting PFAS — per- and polyfluoroalkyl substances, sometimes called "forever chemicals."

3M manufactured PFAS-containing products for decades. These chemicals are now found in water supplies, soil, and even human blood across the globe. The health concerns are serious, and the legal liability is massive.

Here is what we know about the financial exposure:

Public water supply settlement: 3M agreed to pay $10.3B over 13 years (2024-2036) to settle claims from U.S. public water suppliers
Earplug litigation: Settled for approximately $6B for military earplug defect claims
Ongoing exposure: Additional state-level lawsuits, international claims, and private property contamination cases are still pending

The total cash outflow from these settlements is likely $16-20B spread over the next decade. That is significant — it is why FCF has been depressed and why 3M's book value is so low.

The bull case says: "The worst is known and priced in." The bear case says: "Legal liabilities have a way of expanding beyond initial estimates."

Both are valid. This is a genuine uncertainty, and anyone buying 3M needs to be comfortable with that ambiguity.

Who Should Own 3M?

Turnaround investors who believe the post-spinoff 3M will execute on margin recovery and FCF normalization within 2-3 years
Long-term holders who bought lower and are willing to ride out the litigation payments for the new dividend growth trajectory
NOT income investors looking for reliable, growing income — the 1.94% yield and broken streak make CL, KO, or JNJ better options
NOT value investors at the current price — Graham Number and DCF both suggest $85-100 fair value versus $156 stock price

Last updated: March 2026. For the latest 3M financial data, visit StockAnalysis.com.